CorMedix to Unveil 2025 Results and Corporate Update Amid Anti-Infective Expansion

Event summary

  • CorMedix will report Q4 and full-year 2025 financial results on March 5, 2026.
  • The company acquired Melinta Therapeutics in August 2025, expanding its anti-infective portfolio.
  • REZZAYO Phase III study results for IFD prophylaxis expected in Q2 2026.
  • DefenCath is being developed for additional indications including TPN and pediatric hemodialysis.

The big picture

CorMedix's strategic shift toward anti-infectives through the Melinta acquisition positions it in a growing market, but success hinges on effective integration and clinical validation. The company's expansion into new therapeutic areas comes as the biopharmaceutical sector faces increasing pressure to deliver innovative solutions amid rising antimicrobial resistance.

What we're watching

Integration Challenges
How CorMedix will integrate Melinta's portfolio and sustain growth momentum.
Clinical Milestones
Whether REZZAYO's Phase III results will support expanded indications.
Market Positioning
The pace at which CorMedix can differentiate itself in the competitive anti-infectives space.